Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | CTNNB1 | P35222 | 5/20 | 0.47 |
| ▸ | TCF7L2 | Q9NQB0 | 5/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5131563 | 0.89 | CTNNB1 (0.41) | PTPN1CTNNB1TCF7L2MCHR1MAPT | |
| SCHEMBL3336316 | 0.87 | PTPN1 (0.50) | PTPN1CTNNB1TCF7L2MCHR1SMN1; SMN2 | |
| SCHEMBL3336896 | 0.87 | PTPN1 (0.46) | PTPN1CTNNB1TCF7L2MCHR1PTPN6 | |
| SCHEMBL3337583 | 0.85 | MAP4K4 (0.47) | RAB9ANPC1 | |
| SCHEMBL3335192 | 0.84 | TTK (0.47) | SMN1; SMN2MAPTGAA | |
| SCHEMBL3338030 | 0.84 | PLK1 (0.46) | MCHR1SMN1; SMN2TP53MMP9MAPT | |
| SCHEMBL823664 | 0.83 | PTPN1 (0.52) | PTPN1MCHR1SMN1; SMN2TP53RAB9A | |
| SCHEMBL3336819 | 0.83 | DHFR (0.39) | MCHR1MMP9 | |
| SCHEMBL3340058 | 0.83 | IP6K1 (0.45) | RAB9ANPC1 | |
| SCHEMBL3337673 | 0.82 | JAK2 (0.51) | MCHR1MMP9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | PTPN1 1466/4885CTNNB1 2971/4885TCF7L2 763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.